GRID
GRID showed that regorafenib held back GIST that had already escaped both imatinib and sunitinib, and gave patients a third line of targeted treatment.
Overview
GRID randomised 199 patients with metastatic or unresectable gastrointestinal stromal tumour that had progressed on imatinib and sunitinib two to one to regorafenib, a multikinase inhibitor of KIT, PDGFRA and VEGF receptors, or placebo, with crossover at progression. The primary endpoint was progression-free survival.
Regorafenib lengthened progression-free survival several-fold compared with placebo, with disease control in most patients, at the cost of hand-foot skin reaction, hypertension and diarrhoea. Overall survival was confounded by crossover. Regorafenib was approved in the United States in February 2013 as third-line therapy for GIST and held that place until ripretinib arrived in 2020.
Similar pages
not linked directly; found by shared links- TrialREGOBONE
Shares Regorafenib, Bayer, Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
- TrialNAVIGATOR
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
- TrialARANOTE
Shares Bayer and the tag subtype-trials.
- TrialARAMIS
Shares Bayer and the tag subtype-trials.
- TrialCABONE
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
- TrialSARC028
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
- TrialTAPPAS
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
- PersonSebastian Bauer
Shares Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST).